Kind of starting to agree with you. Have kept all shares, probably should have took some profits when it was near .50
They may have technology to disrupt the industry, so did Nikola Tesla. Things didn’t work out. In this situation I think they keep pushing things out, until US removes from schedule 1. At that point they will be bought up for a discount due to low market cap. Thinking it’s more realistic that a deal is struck that will pay shareholders a buck or 2 per share if lucky upon buy out, rather than watching this thing run like a beaten dog. It’s getting hard to view a positive outcome for shareholders. Seems like the closer to legalization we get, cheaper we go here. Currently don’t have any drugs or formulations in clinicals, biosynthesis trying to scale up for the last 2 years, will keep getting pushed out until Lilly can do it themselves and own the rights to all of it. Not trying to be negative, looking at this from a different angle instead of just taking in the same sh*+ we’ve been fed for 2+ years. Hell I think they are still trying to dial in EB medication as they took a cannabinoid out recently, to only include 1 in formulation.
News 
Market Data 
Discover 
AI
